A Genetic Cause for Kidney Cancer
UNC scientists have discovered some really interesting information about how RCCC develops, providing new pathways for targeted therapies. Targeted therapies are those that work by zeroing in on a specific pathway in the cancer ’s development. In this case, Qing Zhang, PhD, and his team of fellow scientists saw that in 90% of RCCC, an important tumor suppressor gene called VHL was either missing or malfunctioning. When this happens, a protein called ZHX2 accumulates in high quantities in the renal cells. The VHL gene l oss is responsible in not only in the origination of the tumor(s), but also plays a key role in their d...
Source: Kidney Cancer Association - September 4, 2018 Category: Urology & Nephrology Source Type: news
Imaging for Screening and Surveillance of Patients with Hereditary Forms of Renal Cell Carcinoma
According to the University of Texas, 5-8% of RCC cases are hereditary.08/29/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2018 Category: Urology & Nephrology Source Type: news
Immunotherapy: What Makes this Cancer Treatment So Promising?
Immunotherapy to treat cancer has been around for a while, but new research is making headway in directions that are both exciting and are giving hope to patients fighting cancer.
In this video, Dr Shubham Pant, an oncologist in Houston Texas, demystifies immunotherapy.08/28/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 28, 2018 Category: Urology & Nephrology Source Type: news
Young Investigator Award winner Dr. Liam Macleod discusses his research on regionalization
Since 2006, the Kidney Cancer Association has supported an annual Young Investigator Award (YIA) through the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). The YIA supported by Kidney Cancer Association provides funding to promising doctors to pursue careers in kidney cancer research.
This year, the Kidney Cancer Association supported two awards – a YIA and an ASCO Annual Meeting Merit Award – through the Conquer Cancer Foundation. The 2018 Conquer Cancer Foundation of ASCO/Kidney Cancer Association YIA recipient, Liam C. Macleod, M.D., M.P.H., is currently completing his s econd year ...
Source: Kidney Cancer Association - August 28, 2018 Category: Urology & Nephrology Source Type: news
My patients are dying. But it ’s their right to keep going.
Isaac Chan, a medical oncology fellow at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discusses a patient's right to refuse palliative care.08/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 27, 2018 Category: Urology & Nephrology Source Type: news
Kuzel Discusses Treatment Options for Metastatic RCC Based on Risk Stratification
Dr. Kuzel discusses treatment options for metastatic RCC based on risk stratification. In the article, Dr. Kuzel talks about two different case scenarios.08/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 27, 2018 Category: Urology & Nephrology Source Type: news
"Kidney Cancer" Journal Release New Issue
The newest issue of the journal, “Kidney Cancer” just came out! The issue includes two review articles on the topics of diagnostic imaging and adjuvant therapy, a commentary about partial nephrectomy and five research articles, plus a new Clinical Trials Corner.08/24/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 24, 2018 Category: Urology & Nephrology Source Type: news
Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma
Although a subset of clear cell renal cell carcinoma (ccRCC) patients respond to immune checkpoint blockade (ICB), predictors of response remain uncertain.08/24/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 24, 2018 Category: Urology & Nephrology Source Type: news
Selecting Patients With Renal Cell Carcinoma for Adjuvant Sunitinib Therapy
Daniel J. George, MD, professor of medicine and surgery at Duke Cancer Institute, discusses his rationale for choosing patients with renal cell carcinoma (RCC) that should receive adjuvant sunitinib (Sutent) therapy.08/23/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 23, 2018 Category: Urology & Nephrology Source Type: news
African Americans Urged To Consider Clinical Trials
An initiative launched today encourages newly-diagnosed African American cancer patients in Maryland to consider clinical trials as the first-line option, not the last resort. The ads are intended to reward those progressive physicians who are actively supporting their patients ’ access to the most advanced options for improved care, including clinical trials for prostate, bladder and kidney cancer.08/23/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 23, 2018 Category: Urology & Nephrology Source Type: news
Diabetes Can Develop in Cancer Patients Treated With Checkpoint Inhibitors
Cancer treatment has been transformed by the use of monoclonal antibodies (mAbs) that block immune inhibitory ligands CTLA-4 and PD-1, known as immune checkpoint inhibitors (CPIs).
With these options for treatment of cancers that are resistant to conventional cancer therapies, the life expectancy of patients with melanoma, lung cancer, renal cell carcinoma, and other cancers, has shown significant improvement. However, according to the journal Diabetes, some patients experience adverse effects. One percent of patients treated with anti –PD-1 or –PD-L1 CPIs develop diabetes.08/22/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 22, 2018 Category: Urology & Nephrology Source Type: news
Case Studies: Treatment of Refractory Metastatic Renal Cell Carcinoma
Thomas Hutson, DO, PharmD, reviews the case of a 70-year old woman who presents with symptomatic, metastatic clear cell renal cell carcinoma.08/21/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 21, 2018 Category: Urology & Nephrology Source Type: news
Personalized Medicine Continues to Evolve in Oncology
The use of next-generation sequencing (NGS) is a novel means of improving cancer care, but there are other methods of improving care that extend beyond the panel itself, explained Leonid Shunyakov, MD, a hematologist/oncologist at Central Care Cancer Center.08/21/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 21, 2018 Category: Urology & Nephrology Source Type: news
Case Studies: Perspective on the Treatment of Advanced Renal Cell Cancer
In this video, Dr. Robert J. Motzer discusses the treatment methods he used on a 49-year-old male with recurrent RCC.08/21/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 21, 2018 Category: Urology & Nephrology Source Type: news
VTE Risk May Hurt Survival After Kidney Cancer Surgery
All-cause mortality was significantly higher among renal cell carcinoma (RCC) patients who developed symptomatic venous thromboembolism (VTE) after undergoing nephrectomy and inferior vena cava (IVC) tumor thrombectomy (TT) accompanied by intravascular tumor thrombosis, a retrospective analysis showed.08/20/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 20, 2018 Category: Urology & Nephrology Source Type: news
